Insight Molecular Diagnostics (IMDX) Cash from Investing Activities (2020 - 2025)
Insight Molecular Diagnostics (IMDX) has disclosed Cash from Investing Activities for 6 consecutive years, with -$1.5 million as the latest value for Q4 2025.
- Quarterly Cash from Investing Activities fell 604.29% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.2 million through Dec 2025, down 522.07% year-over-year, with the annual reading at -$3.2 million for FY2025, 522.07% down from the prior year.
- Cash from Investing Activities hit -$1.5 million in Q4 2025 for Insight Molecular Diagnostics, down from -$1.0 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $214000.0 in Q3 2023 to a low of -$8.3 million in Q1 2021.
- Historically, Cash from Investing Activities has averaged -$1.1 million across 5 years, with a median of -$397500.0 in 2021.
- Biggest five-year swings in Cash from Investing Activities: soared 124.91% in 2023 and later crashed 1179.17% in 2025.
- Year by year, Cash from Investing Activities stood at -$401000.0 in 2021, then tumbled by 100.0% to -$802000.0 in 2022, then soared by 112.84% to $103000.0 in 2023, then crashed by 303.88% to -$210000.0 in 2024, then tumbled by 604.29% to -$1.5 million in 2025.
- Business Quant data shows Cash from Investing Activities for IMDX at -$1.5 million in Q4 2025, -$1.0 million in Q3 2025, and -$349000.0 in Q2 2025.